PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine
- PMID: 23503422
- PMCID: PMC3739227
- DOI: 10.1038/aja.2013.14
PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine
Comment on
-
PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.Mol Cancer Res. 2012 Dec;10(12):1555-66. doi: 10.1158/1541-7786.MCR-12-0314. Mol Cancer Res. 2012. PMID: 23258495 Free PMC article.
References
-
- Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–9. - PubMed
-
- Attard G, de Bono JS. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res. 2011;17:3867–75. - PubMed
-
- Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2012;11:201–14. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
